BioSpace News Archive

Business

BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility

BioNTech SE (Nasdaq: BNTX) today announced that it has agreed a Letter of Intent with the State of Victoria in Australia on a strategic partnership between the State and BioNTech to collaborate on the research and development of potential mRNA-based vaccines and therapies.

October 6, 2022
·
6 min read
Job Trends

Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today issued the following announcement regarding data from two real-world evidence studies evaluating LAGEVRIO™ (molnupiravir), an investigational oral antiviral COVID-19 medicine.

October 6, 2022
·
26 min read
FDA

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved a label expansion for OXLUMO® (lumasiran).

October 6, 2022
·
14 min read
BioMidwest

First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering

First Wave BioPharma, Inc. announced the pricing of a public offering of 3,438,396 shares of its common stock and warrants to purchase up to an aggregate of 3,438,396 shares of its common stock at an offering price to the public of $1.745 per share and associated warrant.

October 6, 2022
·
5 min read
Genetown

Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - October 07, 2022

Amylyx Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00 per share.

October 6, 2022
·
3 min read
Pharm Country

Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering

Avenue Therapeutics, Inc., a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, announced the pricing of its underwritten public offering of 3,636,365 common and pre-funded units.

October 6, 2022
·
5 min read